CIRARA by Remedy Pharmaceuticals receives Orphan Drug Status
US Food and Drug Administration (FDA) has announced orphan drug designation for CIRARA.
Release Date: 07-Feb-2017
US Food and Drug Administration (FDA) has announced orphan drug designation for CIRARA, an investigational drug developed by Remedy Pharmaceuticals, a privately owned pharmaceutical company dedicated to develop lifesaving hospital based treatments for the diseases in central nervous system. The drug has been approved for the designation for the treatment of patients with severe cerebral edema in patients with acute ischemic stroke.
CIRARA is a high affinity inhibitor of Sur1-Trpm4 channels up-regulated following ischemia and trauma. Opening of these channels can lead to chronic edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death.
FDA's Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug status. Once a drug has received orphan drug designation, the developer qualifies for a range of benefits, including federal grants, tax credits, reduction in certain regulatory fees, and the potential for seven years of market exclusivity for the drug following FDA marketing approval.
For Orphan Drug Clinical Insight Reports Contact: email@example.com
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.